Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.68 (market cap $58.74B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.7 (market cap $330.98M). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is far larger — about 177.5× Roundhill S&P 500 0DTE Covered Call Strategy ETF's market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while Roundhill S&P 500 0DTE Covered Call Strategy ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 1 Days and Roundhill S&P 500 0DTE Covered Call Strategy ETF for 54 Days on average.
| TAK | XDTE | |
|---|---|---|
Market Cap | $58.74B | $330.98M |
Volume | 3,110,994 | 194,030 |
Sector | Health | Income / Options Overlay |
52-Week High | $19.05 | $44.76 |
52-Week Low | $13.23 | $36.00 |
Typical Hold Time | 1 Days | 54 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XDTE trades at $38.71, down 0.32% on the day, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong weekly dividend activity, though financial ratios are not disclosed. Recent news highlights its role in weekly income ETF strategies but questions the sustainability of its high yield.
Outlook is mixed; the fund's covered call strategy offers income but faces risks from overnight gaps and fee comparisons. Investors should weigh the attractive yield against potential capital erosion and competitive pressures in the ETF space.
Trailing returns across standard periods
Latest headlines on both assets
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →